PTSM: Pharmaceutical Technology Sourcing and Management
The company invested approximately $26 million to update its sterile pharmaceutical and development service suites.
On May 8, 2017, Patheon announced that it has completed an expansion project at its Greenville, NC manufacturing site. The company invested approximately $26 million to update its sterile pharmaceutical development service (PDS) suite and to build an integrated sterile PDS suite that is compliant with regulatory authorities. The PDS suites provide 7000-square-feet in GMP sterile manufacturing space.
The newly built PDS suite will manufacture sterile liquid and lyophilized drug products. It features freeze dryers and a fully integrated filling line fitted with a restricted access barrier system for sterile drug products. The company has made the investment in disposable manufacturing in this suite eliminating the need for cleaning verification for liquid filling, reducing set up time/product losses, and enhancing sterility assurance. This suite is fully integrated and designed for products in clinical development with the ability to scale up to much larger batch sizes.
Patheon will be attending the CPhI North America conference in Philadelphia, PA from May 16–18, 2017. The company is hosting a panel session at the conference on May 16, 2017.
Source: Patheon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.